He has got to go down as one of the worst pharma CEO in history. So many missed opportunities. Not to mention burning any and all goodwill that Allergan ever had at the stake.
Saunders is just happy that headlines don’t read: “David Tepper of Appoloosa gets Brent Saunders head on a Pike” In a way he did, but it would have been more satisfying if Tepper had forced him out, given more time he would have prevailed. The sale to Abbvie is as close as Saunders could get to an exit strategy. He still has egg on his face but at least he’s not covered in shit. Too bad it will cost the rest of us our paychecks.
how much does he make off of this deal? $300 mil? Amazing That they kept him around after that whole Indian reservation debacle. But I would sell you my reputation for 300 million any day of the week
You know what is sad??? He is leading Allergan in a sale (not a merger) to Abbvie....where Allergan will soon be forgotten forever. Due to the sale of Allergan to Abbvie, hundreds if not thousands of Allergan/Actavis/Watson/Forest employees will be laid off and jobless. Brett Saunders will receive a fat "golden parachute" because of his time at Allergan. Brett Saunders will become the CEO of another (much smaller) pharma company within 2 years of the Allergan - Abbvie deal closing. Any thoughts?
Uh, Allergan and Botox will keep those names. It’s everyone that has nothing to do with Botox that will be gone and forgotten forever.
More on the fabulous growth pharma Brent Allergan CEO Saunders lines up for $39M parachute after AbbVie buy
......and he gets a seat on Abbvie’s Board. He is probably thinking once the current Abbvie CEO retires he has a chance at the top job
Bizarro world Saunders likely isn't bemoaning his Allergan payout, he's not quite where he might have been had Pfizer's proposed $160 billion buyout of the Dublin drugmaker not succumbed in 2016 under new U.S. tax rules. After heading up Forest Labs and then its buyer Actavis, Saunders took the helm of the combined Allergan-Actavis after the two merged. Many assumed that a Pfizer Allergan buy would put Saunders in line to succeed Pfizer's Ian Read—a job that ultimately went to Pfizer COO Albert Bourla. Allergan CEO Saunders lines up for $39M parachute after AbbVie buy
